CClinicalTrials.gg
CompletedNCT00211783Updated Jun 28, 2012

Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism

An observational study in Autism and Asperger's Syndrome, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-28.

Sponsored by Icahn School of Medicine at Mount Sinai · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
71
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study investigates face processing, response inhibition and phoneme processing in autistic adults by fMRI.

Read the detailed description

Fifteen adult outpatients with high functioning autism or Asperger's Syndrome will be recruited. Fifteen healthy volunteers matched for age and IQ will also be recruited. Participants will undergo an fMRI scan. During the scan they will perform a task. The paradigm is designed to test control inhibition, face processing and language. Therefore, it includes a go-no go test, a face emotion discrimination test and a linguistic sound. The subjects are shown a series of faces with happy or sad expressions in random order. Each face presentation is accompanied by either a standard or variant sound. The sound stimulus is the English phoneme /oe/. The variant sound was created by raising the frequency of the standard sound by 20%. The task consists of four blocks. During each block the subjects are asked to press a button when they see a happy or sad face depending on the block. Each block consists of 96 trials lasting 2 seconds and an initial and final fixation period of 40 sec. For each trial the target image is projected for 500 ms. There is 1250 ms fixation time allowed for response and 250 ms for jitter. Twenty-four of the 96 trials are no go trials and 16/96 are sound oddball trials. The oddball is at least two trials apart (between two variant sounds there are at least two standard sounds). There are 24 faces displayed in total, 12 female and 12 male. Faces switch every 16 trials. Face genders are balanced. The faces were selected with over 80% congruency except for two faces with congruency of over 72%. The correlation between sound (2 conditions: standard versus variant) and target condition (go-no go) is zero. The task was piloted on healthy controls and autistic adults. All subjects performed well.

02

Conditions studied

  • Autism
  • Asperger's Syndrome

Keywords

  • autism
  • fMRI
  • response inhibition
  • face processing
  • linguistic processing
03

In context

Autistic Disorder

1,344 studies on the registry are indexed under Autistic Disorder; 334 are open to participants now.

This study's enrollment of 71 is below the median of 102 across 267 observational studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Icahn School of Medicine at Mount Sinai is the lead sponsor of 764 studies on the registry; 181 are open to participants now.

Of its 121 completed or terminated interventional studies of FDA-regulated products, 82 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Thirty adults with ASD and 30

Inclusion criteria

  • Age range of 18-50 years old
  • Diagnosis: autism spectrum disorder by Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) and Autism Diagnostic Interview - Revised (ADI-R)
  • Intelligence quotient (IQ) > 80
  • Outpatients

Exclusion criteria

Exclusion Criteria:

  • Subjects with epilepsy
  • Subjects with history of schizophrenia, schizoaffective disorder or other Axis 1 mental disorders, such as bipolar disorder
  • Subjects reporting history of encephalitis, phenylketonuria, tuberous sclerosis, fragile X syndrome, anoxia during birth, neurofibromatosis, hypomelanosis of Ito, hypothyroidism, Duchenne muscular dystrophy, and maternal rubella
  • Subjects who have received depot neuroleptic medication, or other psychoactive drugs within the past 5 weeks.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
71 participants (actual)

Groups and cohorts

  • Autism

    Procedure: fMRI

  • Control

Interventions

  • ProcedurefMRI

    there is no intervention

06

What researchers measure

Primary outcomes

  1. BOLD

    Differences in BOLD betweens controls and ASD group BOLD - blood-oxygen-level-dependent contrast

    Time frame: at single study visit

07

Study locations

1 site
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00211783
Lead sponsor
Icahn School of Medicine at Mount Sinai
Responsible party
Sponsor
First posted
Sep 21, 2005
Start date
Nov 2004
Primary completion
Nov 2011
Completion
Jun 2012
Last update
Jun 28, 2012

Study contacts

Evdokia Anagnostou
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion